论文部分内容阅读
目的评价荷丹片对代谢综合征(MS)患者糖脂代谢及胰岛素抵抗的作用。方法 120例MS患者随机分为2组,对照组60例,按高脂血症的不同类型,高甘油三酯(TG)者给予非诺贝特0.25g,每晚1次口服;高胆固醇或混合性高脂血症者给予瑞舒伐他汀钙10mg,每晚1次口服。治疗组60例,在对照组治疗基础上加用荷丹片2片,每日3次口服。2组均2个月为1疗程,1个疗程后观察疗效及不良反应。结果治疗后治疗组体质量指数、腰围、空腹血糖、餐后2小时血糖、TG、总胆固醇、低密度脂蛋白胆固醇、胰岛素抵抗指数均有下降,高密度脂蛋白胆固醇上升(P<0.05或P<0.01);对照组TG、低密度脂蛋白胆固醇、空腹血糖、餐后2h血糖下降(P均<0.05)。上述指标治疗组均优于对照组,差异有统计学意义(P均<0.05)。结论降脂药物伍用荷丹片能有效降低MS患者血脂水平,升高高密度脂蛋白胆固醇,减轻胰岛素抵抗程度,改善MS所致糖脂代谢紊乱。
Objective To evaluate the effects of Haldan tablets on glucose and lipid metabolism and insulin resistance in patients with metabolic syndrome (MS). Methods One hundred and twenty patients with MS were randomly divided into two groups. The control group consisted of 60 patients. According to different types of hyperlipidemia, patients with high triglyceride (TG) were given fenofibrate 0.25g orally once daily. Patients with high cholesterol or Mixed hyperlipidemia were given rosuvastatin calcium 10mg, 1 night orally. The treatment group of 60 cases, in the control group based on the treatment plus add dlodine tablets 2, 3 times a day orally. 2 groups were 2 months for a course of treatment, a course of treatment to observe the efficacy and adverse reactions. Results After treatment, body mass index, waist circumference, fasting blood glucose, postprandial blood glucose, TG, total cholesterol, low density lipoprotein cholesterol, insulin resistance index decreased, high density lipoprotein cholesterol increased (P <0.05 or P <0.01). TG, LDL cholesterol, fasting blood glucose and 2h postprandial blood glucose decreased in the control group (all P <0.05). The above indexes were better than the control group, the difference was statistically significant (P all <0.05). Conclusion The lipid-lowering drug Wu Lo Dan tablets can effectively reduce the blood lipid levels of MS patients, raise high-density lipoprotein cholesterol, reduce the degree of insulin resistance and improve MS-induced glucose and lipid metabolism disorders.